We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » INTERNATIONAL HEREDITARY BREAST CANCER TRIAL BEGINS

INTERNATIONAL HEREDITARY BREAST CANCER TRIAL BEGINS

May 3, 2006

The first international clinical trial to treat women with recurring hereditary breast cancer has been launched in Europe, America, Australia and Israel. It will compare carboplatin -- a platinum-based drug normally used to treat ovarian cancer -- with standard chemotherapy. If the tests are successful, scientists believe the drug could be made available to patients within five years. Researchers from University College London, Guy's and St Thomas' NHS Foundation Trust, and the cancer division of the Medical Research Council, are conducting the study.

Approximately 5 percent of breast cancers occur in women with a strong family history of the illness, and more than three quarters of these families will have faulty BRCA1 or BRCA2 genes, noted the researchers. Women who inherit changes in these genes have as much as an 85% chance of developing breast cancer by the age of 70, and around a quarter of these women are likely to relapse.

There is currently no treatment specifically tailored for women with faulty BRCA genes who have recurring breast cancer. Previous laboratory work, however, suggests that carboplatin is 20 times more effective on cancer cells than standard chemotherapy.

"Because this is an established drug which is routinely used for the treatment of ovarian cancer, it has moved swiftly into trials and could be available to patients within five years if it proves to be effective," said James Mackay, one of the study's resaechers.

The study subjects will be randomly selected to receive either carboplatin or docetaxel, the current best-standard breast cancer chemotherapy drug. It is hoped 150 women from hospitals across the world will take part in the trial over a four-year-period, added Mackay.

KEYWORDS Daily International Pharma Alert

Upcoming Events

  • 08Sep

    Organizing Data and Document Archives: Finding a Needle in a Haystack for FDA Inspections

  • 15Sep

    Califf’s Post-PDUFA, Post-COVID FDA Agenda: Key Developments, Insights and Analysis

  • 20Sep

    Building a World-Class Pharmaceutical Advertising and Promotion Review Program

  • 21Sep

    The FDA’s Focus on Clinical Data Integrity Throughout Product Development and Approval

  • 22Sep

    FDA’s New Quality Management System Regulation: What the Proposed Harmonization with ISO 13485 Means for Devicemakers

  • 11Oct

    1st Annual Quality Management vSummit

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • Hyris T-Cell Test Gains CE-IVD Mark

  • FDA Expands Approval of Bayer’s Nubeqa for Prostate Cancer

  • MicroPort Navibot Receives 510(k) Clearance for Its SkyWalker System

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing